Related Experiment Videos
The antihypertensive effect of verapamil in patients with chronic renal failure
J L Rodicio1, J M Alcazar, L M Ruilope
1University of Madrid, Hospital 12 de Octubre, Spain.
Insights
Verapamil effectively reduces hypertension in chronic renal failure patients, regardless of sodium intake. It also helps manage proteinuria, making it a valuable treatment option.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Hypertension is a common complication in chronic renal failure (CRF).
- Dietary sodium and protein intake can influence blood pressure and proteinuria in CRF patients.
- Calcium channel blockers, like verapamil, are used to manage hypertension.
Purpose of the Study:
- To evaluate the efficacy of verapamil-SR in reducing hypertension in CRF patients on varying sodium diets.
- To assess the impact of verapamil-SR on proteinuria in CRF patients on normal and low-protein diets.
Main Methods:
- A study involving patients with chronic renal failure and hypertension.
- Administration of verapamil-SR 240 mg daily.
- Monitoring of blood pressure and proteinuria levels under different dietary conditions (low/high sodium, normal/low protein).
Main Results:
- Verapamil-SR (240 mg daily) effectively reduced hypertension in CRF patients.
- The antihypertensive effect of verapamil was consistent across both high and low sodium intake groups.
- Verapamil-SR helped maintain reduced proteinuria in CRF patients on low-protein diets and showed potential in preventing proteinuria in those on normal-protein diets.
Conclusions:
- Verapamil-SR 240 mg daily is an effective treatment for hypertension in chronic renal failure patients.
- Its efficacy is not affected by sodium intake levels.
- Verapamil-SR demonstrates beneficial effects on proteinuria management in CRF patients, particularly those on protein-restricted diets.
Abstract:
The calcium antagonist verapamil has been demonstrated to be effective in reducing hypertension in patients in whom sodium intake was not restricted. The present study evaluated the effect of verapamil in reducing hypertension in patients with chronic renal failure on low or high sodium diets. Also, the present study evaluated the effect of verapamil on proteinuria in chronic renal failure patients who were administered a normal and low protein diet. The results reveal that verapamil-SR 240 mg daily is effective in reducing hypertension in patients with chronic renal failure and the effect of verapamil is equal in patients on a high or low sodium intake. In addition, verapamil-SR 240 mg daily is effective in maintaining reduced proteinuria in chronic renal failure patients on low protein diet and may prevent proteinuria in such patients on a normal protein diet. Therefore, verapamil-SR 240 mg daily appears to be an excellent choice for the treatment of hypertensive chronic renal failure patients.